Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies

Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies

Intravenous immunoglobulins represent an established therapy for the treatment of chronic immune-mediated neuropathies, specifically chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) as well as multifocal motor neuropathies (MMNs). For the treatment of antibody deficiency syndromes...

Full description

Bibliographic Details
Main Authors:	Verena I. Leussink, Hans-Peter Hartung, Bernd C. Kieseier, Mark Stettner
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-07-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756285616641583

Similar Items

Review: Pathogenesis and treatment of immune-mediated neuropathies
by: Helmar C. Lehmann, et al.
Published: (2009-07-01)

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
by: Verena Isabell Leussink, et al.
Published: (2012-09-01)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
by: Luca Gentile, et al.
Published: (2021-04-01)

Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy
by: Michael Fleischer, et al.
Published: (2021-04-01)

Focus on LPA signaling: a promising therapeutic target to foster regeneration in immune-mediated neuropathies
by: Fabian Szepanowski, et al.
Published: (2023-01-01)

Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia
by: S. Shahzad Mustafa, et al.
Published: (2021-01-01)

Atacicept: targeting B cells in multiple sclerosis
by: Hans-Peter Hartung, et al.
Published: (2010-07-01)

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy
by: Juliane Klehmet, et al.
Published: (2023-05-01)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
by: Suzanne Skoda-Smith, et al.
Published: (2009-12-01)

Tissue mRNA expression in rat of newly described matrix metalloproteinases
by: FABIÁN BERNAL, et al.
Published: (2005-01-01)

Acute Inflammatory Demyelinating Neuropathy : Immunoglobulin And Immune Complex Profile
by: Shripad A, et al.
Published: (2003-01-01)

Novel pathomechanisms in inflammatory neuropathies
by: David Schafflick, et al.
Published: (2017-11-01)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
by: Dario Cocito, et al.
Published: (2023-11-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
by: Edina Kovács, et al.
Published: (2017-11-01)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
by: Chapdelaine H, et al.
Published: (2012-11-01)

High-dose immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
by: Satomi Hiya, et al.
Published: (2022-06-01)

Subcutaneous immunoglobulin replacement therapy: the European experience.
by: Chapel, H, et al.
Published: (2013)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
by: P R Bourque, et al.
Published: (2016-01-01)

Promoting myelination in an in vitro mouse model of the peripheral nervous system: the effect of wine ingredients [corrected].
by: Mark Stettner, et al.
Published: (2013-01-01)

Immune-Mediated Neuropathies: Pathophysiology and Management
by: Abhishek Shastri, et al.
Published: (2023-04-01)

Time for a standardized diagnostic response test in patients with chronic inflammatory demyelinating polyradiculoneuropathy?
by: Fabian Szepanowski, et al.
Published: (2023-11-01)

Neuropathy and neural plasticity in the subcutaneous white adipose depot.
by: Magdalena Blaszkiewicz, et al.
Published: (2019-01-01)

Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry
by: Martin Stangel, et al.
Published: (2016-05-01)

Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study
by: Jeremias Motte, et al.
Published: (2021-03-01)

Outcome evaluation of a subcutaneous immunoglobulin clinical management program
by: Julia Zhu, et al.
Published: (2019-01-01)

Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia
by: John-Ih Lee, et al.
Published: (2020-07-01)

Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
by: Scheuerlein, P, et al.
Published: (2018)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
by: Philipp Scheuerlein, et al.
Published: (2018-07-01)

Immune mediated neuropathies in pregnancy and postpartum period
by: Reza Boostani, et al.
Published: (2021-04-01)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
by: Clémence Perraudin, et al.
Published: (2020-01-01)

Assessment of local adverse reactions to subcutaneous immunoglobulin (SCIG) in clinical trials
by: Ballow, M, et al.
Published: (2017)

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
by: Bjorkander, J, et al.
Published: (2000)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
by: Martin Adriana, et al.
Published: (2012-11-01)

Low-dose subcutaneous immunoglobulin is an effective treatment for autoimmune bullous skin disorders: A case report
by: Erin Streu, et al.
Published: (2020-01-01)

Recent advances in the diagnosis of immune mediated demyelinating neuropathies
by: Shilpa Rao, et al.
Published: (2022-01-01)

Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection
by: Gastón J Piñeiro, et al.
Published: (2018-10-01)

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
by: Ducruet Thierry, et al.
Published: (2011-11-01)

Subcutaneous immunoglobulin therapy for immunomodulation in a patient with severe epidermolysis bullosa acquisita.
by: Tayal, U, et al.
Published: (2008)